K
Keros Therapeutics, Inc. (KROS)
NGM – Real Time Price. Currency in USD
11.65
-0.36 (-3.00%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
11.65
-0.36 (-3.00%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 15.45 | 6.05 | 10 | |
| Quick ratio | 15.45 | 5.63 | 10 | |
| Debt to Equity | 0.06 | 0.30 | 9.0 | |
| Debt to Assets | 0.05 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | 151K | 4M | 244M | 244M |
| Gross Profit | -2M | -664K | 2M | 243M | 243M |
| Operating Income | -115M | -170M | -211M | 71M | 68M |
| Net Income | -105M | -153M | -187M | 87M | 87M |
| EBITDA | -113M | -169M | -210M | 72M | 69M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -99.09 | -130.01 | 1.0 |
| Next quarter | -96.46 | -71.38 | 1.0 |
| Current year | -98.54 | -332.28 | 1.0 |
| Next year | 266.17 | -7.67 | 5.5 |
| Weighted average score | 2.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -97.29 | -222.26 | -377.77 | -979.87 | 1.0 |
| Y/Y | -87.33 | 49.03 | 24.56 | 40.76 | 7.8 |
| 3y average | 3341.65 | 25.95 | 41.52 | 19.6 | 9.8 |
| 5y average | 2184.79 | -5.96 | 14.78 | -4.77 | 5.0 |
| Weighted average score | 5.9 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $287.4M significantly exceed its total debt $16.9M, ensuring strong financial flexibility
Total current assets $315.4M exceed Total current liabilities $20.4M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$27.4M limits the company's ability to reinvest or pay down debt